Deutsche Biotech Innovativ (DBI) AG is a listed biotechnology company based in Hennigsdorf near Berlin that holds shares in different biotech enterprises.
DBI shares (DE000A0Z25L1) are traded on the open market of Dusseldorf Stock Exchange.
DBI was originally founded as
Venetus Beteiligungen AG and changed its name to Deutsche Biotech Innovativ AG in
Founders and Executive Board members of
DBI are Dr. Bernd Wegener (Chief Executive Officer) and Dr. Andreas Bergmann (Chief Scientific Officer).
The Supervisory Board of DBI comprises Renke Lührs (Chairman), Dr. Metod Miklus (Vice Chairman) and Dr. Ute Kilger.
DBI is part of a comprehensive international network of leading scientists, institutes and companies, from the fields of biotechnology, pharma, medicine, and life sciences. This enables access to valuable patient’s data, such as blood samples from clinical trials.
DBI primarily invests in companies that develop drug candidates
with a unique selling point and blockbuster potential.
DBI aims to continuously expand its shareholding portfolio. The portfolio currently comprises four investments:
Adrenomed AG develops the first-in-class monoclonal Adrenomedullin-specific antibody Adrecizumab as a targeted therapy against septic shock to reduce sepsis mortality. Adrecizumab has an excellent toxicology and safety profile and will now be tested in patients with early septic shock (Clinical Phase II).
Oncoprevent GmbH and AngioBiomed GmbH focus on the prevention of breast cancer and inhibition of tumor growth, respectively.
My Life Diagnostics GmbH serves as a think tank for the development of R&D projects.
Learn more ...
Adrecizumab | Targeted therapy against septic Shock
AB2302 | Targeted anti-angiogenic tumor therapy